4CPS-316 Multiple sclerosis outpatient pharmaceutical care by an implanted telepharmacy tool during SARS-CoV-2 pandemic

Abstract

the chest X-ray at day 3 was observed in 7 of the 9 patients, and no radiological worsening was recorded in the 2 other patients. Median SpO 2 at baseline was 92% (IQR 88-95), with a significant improvement of 97% (IQR 96-98) (p=0.007) at day 3. Significant differences were also observed in various laboratory parameters between days 0 and 3. No serious adverse events were observed. On days 3 and 14, no patient had died and none required invasive ventilation. One patient died after 21 days of hospitalisation; the remaining 8 were discharged (length of stay 6-45 days). Conclusion and relevance In this study of patients with refractory moderate-severe COVID-19, a 3 day course of low dose subcutaneous anakinra was effective and safe, resulting in radiological, clinical and analytical improvement in most cases. These observations require further evaluation in clinical trials.